Marc Cantillon, MD
Psychiatry · Livingston, NJNPI 1427037803
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $374,703 of the $522,029 with a category attached, or 71.8%. Acadia Pharmaceuticals Inc accounts for 71.8% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $394,238 and has fallen 91.4% since, to $33,879 in 2025. Among psychiatry clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 656 payments — averaging $795.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$375K
- AbbVie$117K
- E.r. Squibb & Sons, L.L.C.$26K
- Alkermes, Inc.$828
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$651
- Axsome Therapeutics, Inc.$641
- plus $2K from 20 others
Across 1 payment — averaging $1713.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$2K
What the payments were for
- Consulting fees$374,70372%
- Speaking & faculty fees$131,98525%
- Travel & lodging$3,7521%
- Food & beverage$11,4882%
- Education$1010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 23 | $374,982 |
| AbbVie(2 entities) | 369 | $116,710 |
| E.r. Squibb & Sons, L.L.C. | 49 | $25,732 |
| Alkermes, Inc. | 28 | $828 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $651 |
| Axsome Therapeutics, Inc. | 30 | $641 |
| Neurocrine Biosciences, Inc. | 16 | $500 |
| Teva Pharmaceuticals USA, Inc. | 14 | $341 |
| Otsuka America Pharmaceutical, Inc. | 13 | $301 |
| Supernus Pharmaceuticals, Inc. | 4 | $201 |
| Lundbeck LLC | 13 | $200 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $198 |
| Vanda Pharmaceuticals Inc. | 14 | $177 |
| Eisai Inc. | 6 | $150 |
| Almatica Pharma LLC | 5 | $77 |
| Sunovion Pharmaceuticals Inc. | 5 | $73 |
| Jazz Pharmaceuticals Inc. | 3 | $48 |
| Johnson & Johnson | 3 | $40 |
| Luye Pharma (USA) Ltd. | 2 | $36 |
| Indivior Inc. | 2 | $34 |
| Bausch Health US, LLC | 2 | $33 |
| Bioxcel Therapeutics, Inc. | 1 | $20 |
| Neos Therapeutics, LP | 1 | $17 |
| Braeburn Inc. | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $13 |
| Noven Therapeutics, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$522,029 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 127 | $230,446 |
| CaplytaLumateperone Tosylate | 13 | $23,669 |
| ValiumDiazepam | 13 | $19,359 |
| Mirtazapine | 143 | $5,854 |
| Quetiapine Fumarate | 118 | $3,869 |
| Olanzapine | 30 | $2,098 |
| Bupropion XlBupropion Hcl | 63 | $2,063 |
| Duloxetine Hcl | 66 | $1,975 |
| Alprazolam | 200 | $1,900 |
| Clonazepam | 158 | $1,732 |
| Gabapentin | 88 | $1,725 |
| Trazodone Hcl | 35 | $1,709 |
| Aripiprazole | 24 | $1,554 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 21 | $1,548 |
| Ziprasidone Hcl | 19 | $1,498 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $116,710 | $230,446127 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $651 | $23,66913 claims |
| Almatica Pharma LLCSertraline Hcl | $77 | $58235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Other psychiatry in Livingston
- Robert BransfieldRed Bank$415K
- Erika ConcepcionLong Branch$354K
- Leon RosenbergCherry Hill$257K
- Lloyd AlceraMarlton$187K
- Gary SmallHackensack$170K
- Shankar SrinivasanParsippany$155K
- Matthew PiteraToms River$153K
- Boris BorodulinEast Brunswick$116K
- Anthony RostainCamden$110K
- Aijaz NanjianiParamus$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.